This week in Urology
Nov 20, 2026
Which Patients with Advanced Clear Cell Renal Cell Carcinoma Benefit Most from First-line Checkpoint Inhibitor Combination Regimens: A Meta-analysis of Individual Patient Data and Aggregate Data from Randomised Trials.
Across four first-line immunotherapy combination trials in metastatic clear cell kidney cancer, survival benefit over sunitinib was absent in favourable-risk patients and largest in poor-risk patients.
European Urology · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: survival gains from immunotherapy combinations in kidney cancer cluster in poorer-risk disease, urine biomarkers reduce cystoscopy use in bladder cancer surveillance, and saturation biopsy still finds cancers that MRI targeting misses.
Welcome to This Week in Urology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
Richters and colleagues, writing in European Urology, pooled the randomised trials behind first-line immunotherapy combinations for metastatic clear cell renal cell carcinoma, each tested against sunitinib [1]. The meta-analysis covered CheckMate-214, CheckMate-9ER, KEYNOTE-426 and CLEAR, a total of 3320 patients, with individual patient data for the two CheckMate trials, around 1,750 patients, and aggregate data for the other two. Across all four trials, patients in the IMDC favourable-risk group had no significant overall survival benefit, with survival essentially identical between arms. In intermediate-risk patients the risk of death was about a fifth lower, and in poor-risk patients the risk of death was roughly half that seen with sunitinib. Measured as restricted mean survival time in the individual patient data, the gain was about one month for favourable prognosis, not statistically significant, about three months for intermediate prognosis and just over seven months for poor prognosis. PD-L1 expression at a five percent cut-off also modified the treatment effect. The main limitation is that individual data were available for only two of the four trials, and these remain subgroup comparisons against an older control. The analysis adds a patient-level estimate showing that the survival benefit of these combinations is concentrated in higher-risk disease.
In the World Journal of Urology, Abushamma and colleagues report a systematic review and meta-analysis of randomised trials comparing urinary biomarker-guided surveillance with standard cystoscopic surveillance in non-muscle-invasive bladder cancer [2]. Only two trials qualified, DaBlaCa-15 and UroFollow, which together randomised 606 participants. Biomarker-guided surveillance reduced cystoscopy use substantially, by a little over half in DaBlaCa-15 and by about three quarters in UroFollow. There was no significant difference in any recurrence, in high-grade recurrence or progression, or in progression to muscle-invasive or metastatic disease. The authors are explicit that non-inferiority could not be established. The two trials used different surveillance strategies in different risk groups, progression events were uncommon, and the pooled oncological estimates were treated as exploratory. What the review adds is randomised evidence that biomarker-guided surveillance can reduce the number of cystoscopies without a detectable signal of worse recurrence or progression. The authors conclude that larger trials with longer follow-up are needed before such a strategy could replace guideline-based cystoscopy, so the evidence at present supports further testing rather than a change in standard surveillance.
Also in the World Journal of Urology, Wong and colleagues examined whether saturation sampling adds anything once an MRI-targeted biopsy has been taken [3]. This was a retrospective analysis of a prospectively maintained database of transperineal MRI-ultrasound fusion biopsies, covering 1130 paired biopsy episodes in 1050 men, each of whom had targeted cores plus a template saturation biopsy that avoided the MRI targets. Detection of clinically significant cancer, Grade Group 2 or higher, was similar for the two components, at about 36 and 37 percent. Saturation biopsy found more cancer overall, driven largely by Grade Group 1 disease, which it detected in about a fifth of episodes against about a tenth for targeted biopsy. The two components were not interchangeable: the highest grade agreed in just under two thirds of episodes. Omitting saturation would have missed 78 clinically significant cancers, about 16 percent of the total, while omitting targeted cores would have missed 63. The limitation is a single retrospective database in which every man had both techniques, with no downstream outcomes. The study adds paired evidence that the two approaches find different cancers, and the authors call for evaluation of risk-adapted saturation sampling.
Now, four in brief.
Suleja and colleagues, in the World Journal of Urology, pooled 33 studies of HER2-targeted therapy in localized urothelial carcinoma, covering 970 patients, and 30 of those studies tested disitamab vedotin [4]. In neoadjuvant studies of disitamab vedotin regimens, the pooled pathological complete response rate was just under half. The evidence was insufficient to link HER2 expression with response. In bladder-sparing studies, clinical complete response ranged from about two thirds with strict definitions to just over half with definitions allowing residual Ta or carcinoma in situ. Grade 3 or higher adverse events did not exceed about a third, with no grade 5 signal. None of the trials was blinded and response definitions varied, so this is early activity data.
Staying with bladder cancer, McDonald and colleagues in BJU International compared two oral antibiotic strategies after cystectomy with urinary diversion in a single-centre retrospective cohort of 223 patients [5]. Continuous prophylaxis until stent removal meant a median of 16 days of antibiotics against 7 days with a short course around stent removal. Urinary tract infection, surgical site infection and readmission did not differ significantly. Continuous prophylaxis was associated with more new organisms not covered by the regimen, and new Pseudomonas isolation was about 15 percent against under 3 percent, a roughly fivefold rise in the odds after adjustment. The authors describe the before-after design as hypothesis-generating.
In the World Journal of Urology, Miçooğulları and colleagues compared super-pulsed thulium fiber laser retrograde intrarenal surgery with supine and prone percutaneous nephrolithotomy for solitary stones of 20 to 30 millimetres, in 260 patients at one institution [6]. Stone-free rates on the first postoperative day were lower after retrograde surgery, at just under 80 percent. At one month on low-dose CT, stone-free rates did not differ significantly, at about 90 percent or more in all three groups. Retrograde surgery had a smaller haemoglobin drop and a slightly shorter stay, with comparable complications. The design was retrospective and non-randomised, so selection may explain part of the difference.
The Journal of Urology published an amendment to the AUA and SMSNA guideline on disorders of ejaculation, led by Shindel [7]. An updated evidence search identified 89 eligible studies, with 25 assessed in detail. A statement on non-pharmacological therapy for premature ejaculation was revised to reflect evidence that some of these approaches may be effective. A new expert opinion statement addresses PDE5 inhibitors for premature ejaculation. New statements cover daily or on-demand clomipramine and glans hyaluronic acid injection, with the panel stressing informed consent and use by a trained clinician. The PDE5 inhibitor statement rests on expert opinion, and the panel frames shared decision-making as the governing principle.
Three quick signals.
In European Urology Focus, Lopez Sanmiguel and colleagues followed 3812 patients after nephrectomy for localized kidney cancer [8]. Local recurrence was uncommon, at under one in ten by twenty years. A positive margin after minimally invasive surgery was linked with roughly sixfold higher local recurrence risk and about ninefold higher risk of atypical recurrence. The data are observational.
Peng and colleagues, in BJU International, compared robot-assisted with open inferior vena cava thrombectomy in 226 patients at one high-volume centre [9]. The robotic approach was associated with less blood loss, fewer transfusions, fewer complications and shorter stays, with no significant difference in overall or disease-free survival. The open group had only 37 patients and the analysis was retrospective.
In the World Journal of Urology, Scilipoti and colleagues described endoscopic kidney-sparing treatment of synchronous bilateral upper tract urothelial carcinoma in 17 patients at two European centres [10]. Recurrence affected 14 of the 17 patients, three needed nephroureterectomy, and no patient required dialysis. The series is small and retrospective.
Stepping back across this week's papers, the firmest evidence came from pooled randomised trials, yet even there the most useful answers sit in subgroups or in a review resting on very few trials. Most of the remaining work is retrospective and drawn from single centres, and several studies measured intermediate endpoints such as pathological response, early stone clearance or organisms isolated rather than survival or progression. That pattern limits how far any single result can move established practice.
If you only have time for one paper this week, make it the patient-level meta-analysis of first-line immunotherapy combinations in metastatic clear cell kidney cancer [1]. It reopens the question of whether patients with favourable-risk disease gain survival from these combinations at all.
That's your roundup for This Week in Urology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Urology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?